Waldinger M D, Berendsen H H, Schweitzer D H
Department of Psychiatry and Neurosexology, Leyenburg Hospital, Leyweg 275, 2545 CH, The Hague, The Netherlands.
Maturitas. 2000 Oct 31;36(3):165-8. doi: 10.1016/s0378-5122(00)00152-3.
To evaluate the effect of mirtazapine on the severity of hot flushes and bouts of perspiration in women.
In two women with depression a reduction in hot flushes was noticed by serendipity during treatment with mirtazapine 15-30 mg/daily. On the basis of this observation clinical studies were extended with two non-depressed and non-anxious women with hot flushes. Both subjects were prescribed mirtazapine daily.
Four cases are described as case reports. All subjects reported a practically complete disappearance of hot flushes and associated perspiration, within the first week of treatment.
Mirtazapine appears to have a substantial ameliorating effect on hot flushes and perspiration bouts. It is postulated that the 5-HT(2A) blocking properties of mirtazapine is accounted in the symptomatic relief of hot flushes. In addition it is hypothesized that the serotonergic system is crucially involved in the pathogenesis of hot flushes and perspiration bouts. Further evaluation in double-blind placebo-controlled studies is encouraged.
评估米氮平对女性潮热及出汗发作严重程度的影响。
两名抑郁症女性患者在接受每日15 - 30毫克米氮平治疗期间，意外发现潮热有所减轻。基于这一观察结果，对另外两名无抑郁和焦虑症状但有潮热的女性进行了临床研究扩展。两名受试者均每日服用米氮平。
以病例报告形式描述了4例病例。所有受试者均报告在治疗的第一周内潮热及相关出汗现象几乎完全消失。
米氮平似乎对潮热及出汗发作有显著的改善作用。据推测，米氮平的5 - HT(2A)阻断特性是其缓解潮热症状的原因。此外，推测血清素能系统在潮热及出汗发作的发病机制中起关键作用。鼓励进行双盲安慰剂对照研究作进一步评估。
